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Cytarabine (ara-C) is the most effective agent for the treatment of acute myeloid leukaemia (AML). Aberrant expression of enzymes
involved in the transport/metabolism of ara-C could explain drug resistance. We determined mRNA expression of these factors using
quantitative-real-time-PCR in leukemic blasts from children diagnosed with de novo AML. Expression of the inactivating enzyme
pyrimidine nucleotidase-I (PN-I) was 1.8-fold lower in FAB-M5 as compared to FAB-M1/2 (P¼0.007). In vitro sensitivity to
deoxynucleoside analogues was determined using the MTT-assay. Human equilibrative nucleoside transporter-1 (hENT1) mRNA
expression and ara-C sensitivity were significantly correlated (rp¼ 0.46; P¼0.001), with three-fold lower hENT1 mRNA levels in
resistant patients (P¼0.003). hENT1 mRNA expression also seemed to correlate inversely with the LC50 values of cladribine
(rp¼ 0.30; P¼0.04), decitabine (rp¼ 0.29; P¼0.04) and gemcitabine (rp¼ 0.33; P¼0.02). Deoxycytidine kinase (dCK) and
cytidine deaminase (CDA) mRNA expression seemed to correlate with in vitro sensitivity to gemcitabine (rp¼ 0.31; P¼0.03) and
decitabine (rp¼0.33; P¼0.03), respectively. The dCK/PN-I ratio correlated inversely with LC50 values for gemcitabine (rp¼ 0.45,
P¼0.001) and the dCK/CDA ratio seemed to correlate with LC50 values for decitabine (rp¼ 0.29; 0.04). In conclusion, decreased
expression of hENT1, which transports ara-C across the cell membrane, appears to be a major factor in ara-C resistance in childhood
AML.
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Although the treatment of acute leukaemia has improved
significantly over the past few decades, the prognosis of acute
myeloid leukaemia (AML) remains relatively poor. For newly
diagnosed patients, the compete remission (CR) rate reaches 85–
90% with standard induction chemotherapy (Creutzig et al, 1999;
Hann et al, 2004). However, about 30–50% of the patients that
achieve CR relapse from minimal residual disease cells that
apparently survived chemotherapy (Hann et al, 2004), giving rise
to a more resistant leukaemia. Resistance to chemotherapy
therefore remains a major obstacle in the treatment of AML.
In combination with anthracyclines, 1-b-D-arabinofuranosyl-
cytosine (cytosine arabinoside, cytarabine, ara-C) is the most
effective agent for the treatment of AML. Ara-C is a deoxynucleo-
side analogue that has to be converted into its active triphosphate
derivative (ara-CTP) to exert its cytotoxic effect (Grant, 1998). Ara-
CTP is then incorporated into the DNA causing chain termination,
resulting in a block in DNA synthesis and facilitating programmed
cell death (Figure 1). Ara-C is a hydrophilic molecule and as such
requires facilitated diffusion via nucleoside-specific membrane
transport carriers to enter cells (Cass et al, 1998; Clarke et al,
2002). The human equilibrative nucleoside transporter (hENT1) is
responsible for 80% of ara-C influx in human leukemic blast cells
(Sundaram et al, 2001; Clarke et al, 2002). Inside the cell,
conversion of ara-C into ara-CMP by deoxycytidine kinase
(dCK) is believed to be the rate-limiting step in the metabolism
of ara-C (Liliemark et al, 1985; Plunkett et al, 1987). Subsequently,
ara-CMP is phosphorylated into ara-CDP by nucleoside mono-
phosphate kinases, which in turn finally is phosphorylated into
ara-CTP by diphosphate kinases (Hande and Chabner, 1978).
Inactivation of ara-C results from deamination by cytidine
deaminase (CDA) (Laliberte and Momparler, 1994). In addition,
ara-CMP can be dephosphorylated by pyrimidine nucleotidase I
(PN-I) (Amici et al, 1997) as well as deaminated by deoxycytidylate
deaminase (dCMPD) (Mancini and Cheng, 1983). Inactivation by
these enzymes decreases the amount of ara-CTP and thereby limits
ara-C mediated cytotoxicity. Deoxycytidine triphosphate (dCTP) is
thought to inhibit the phosphorylation of ara-C (by feedback
inhibition of dCK) and the incorporation of ara-CTP into DNA (by
competition for DNA polymerase). Increased intracellular dCTP
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spools therefore antagonise the formation of ara-CTP (Liliemark
and Plunkett, 1986; White and Capizzi, 1991). dCTP can be
synthezised directly via the de novo pathway by ribonucleotide
reductase (RR) (Smith and Karp, 2003). Ribonucleotide reductase
catalyses the conversion of ribonucleotides into deoxyribonucleo-
tides (Smith and Karp, 2003). Mammalian RR is made up of two
subunits (Reichard and Ehrenberg, 1983). The M1 subunit is the
binding site for nucleotides and the second subunit, M2, is a metal
binding site that requires both a non-haeme iron and a tyrosine-
free radical for its activity (Smith and Karp, 2003). CTP synthetase
(CTPs) is responsible for the conversion of uridine triphosphate
(UTP) into CTP and has a high activity in several malignancies,
including acute lymphoblastic leukaemia (Verschuur et al, 1998).
In addition to ara-C a variety of other deoxynucleoside
derivatives are active in both haematological and solid malig-
nancies. The purine analogues 2-chlorodeoxyadenosine (cladri-
bine; 2-CdA) and fludarabine (F-ara-A) are active against indolent
lymphoid malignancies and are currently also used for the
treatment of hairy-cell leukaemias and chronic and acute
leukaemias, respectively (Frewin and Johnson, 2001). The pyr-
imidine analogue gemcitabine (dFdC) has activity in various solid
malignancies and some haematological disorders (Van Moorsel
et al, 1997). The cytidine analogue 5-aza-20-deoxycytidine (deci-
tabine; DAC) is a potent hypomethylating agent and has shown to
be active in the treatment of haematological malignancies such as
AML, chronic myeloid leukaemia (CML) and myelodysplastic
syndrome (Lyons et al, 2003). These compounds are activated
intracellularly via the same metabolic pathway as ara-C. Impaired
transport decreased activation of deoxynucleoside analogues to
their cytotoxic tri-phosphate form or increased dCTP levels may
result in resistance to this clinically important group of
compounds. The objective of our study was to identify possible
mechanisms of resistance to deoxnucleoside analogues, particu-
larly ara-C, in the leukemic blasts of paediatric AML patients. We
therefore determined the mRNA level of the following targets:
hENT1, dCK, PN-I, CDA, dCMPD, CTP synthetase and RR (subunit
1 and 2) in leukaemic blasts from children with newly diagnosed
AML. In addition, we studied the mRNA expression levels of the
target enzymes in different AML FAB-type subgroups. Finally, the
expression levels of the above-mentioned enzymes were correlated
to in vitro sensitivity to deoxynucleoside analogues (ara-C, 2-CdA,
DAC, F-ara-A and dFdC).
MATERIALS AND METHODS
Patient samples
Bone marrow and/or peripheral blood samples were collected from
untreated children diagnosed with de novo AML. The following
groups participated in this study and provided patient samples: (1)
The Dutch Childhood Oncology Group (DCOG), The Hague, The
Netherlands; (2) MRC Childhood Leukaemia Working Party, UK
and (3) The AML BFM-study Group, Mu ¨nster, Germany. Central
review of the diagnosis, data collection as well as review of FAB-
classification were carried out by reference laboratories and data
centres of these groups. The FAB-classification was performed
according to the criteria by Bennett et al (1985), including the
modifications to diagnose FAB M0 and FAB M7. Samples were
collected at the VU university medical centre between October
1990 and September 2002.
Treatment protocols
Patients were treated on intensive ara-C/anthracyclines based
protocols in the Netherlands, Germany and the UK (protocols
DCOG AML 87 and 97, BFM 93 and 98 and MRC AML 12). The
treatment protocols have been reported in detail elsewhere
(Creutzig et al, 1995, 1999; Hann et al, 2004; Slats et al, 2005).
In the AML BFM 93 study, the patients were stratified according
to risk group. At diagnosis, patients were randomised between
daunorubicin (plus ara-C and etoposide, ADE) and idarubicin
(plus ara-C and etoposide, AIE) induction therapy. For HR
patients, one of the intensification blocks was changed to high-
dose ara-C with mitoxantrone (HAM). Sibling SCT was advised for
HR patients in first CR. SR patients did not recieve HAM. Protocol
AML BFM 98 consisted of induction with the idarubicin block,
followed by HAM. In the consolidation phase, patients were
randomised for either recieving the 6-week consolidation block
followed by one intensification block vs three intensive courses of
chemotherapy.
The DCOG AML 87 protocol was based on the concurrent AML-
BFM protocol. In brief, DCOG AML 87 started with an 8-day
induction course followed by a 6-week consolidation block. Then
two intensification courses were given. Intrathecal chemotherapy
was given as central nervous system prophylaxis. Contrary to the
AML BFM 87 study, no maintenance therapy was given. Sibling
donor allogeneic STC was advised for HR patients in first CR.
Patients enrolled in the DCOG AML 97, which was identical to
the MRC AML12 protocol, were stratified according to cyto-
genetics. Good risk patients (defined as patients with t(8;21),
inv(16) or t(15;17)) were not eligible for SCT. Patients were
randomised to induction treatment with either ADE (ara-C,
daunorubicin and etoposide) or MAE (mitoxantrone, ara-C and
etoposide), followed by a four or five (randomised) treatment
courses. The fifth course was high-dose ara-C and asparaginase. If
a matched sibling donor was available, then SCT was recom-
mended as the fourth or fifth course (randomised).
Ara-C 
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ara-CMP
ara-CDP
ara-CTP
DNA
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Figure 1 Metabolism of ara-C. Ara-C enters the cell via the equilibrative
nucleoside transporter 1 (hENT1; 1). Inside the cell, ara-C is phosphory-
lated to ara-CMP by deoxycytidine kinase (dCK; 2). Ara-CMP is
subsequently phosphorylated to ara-CTP, the active metabolite. Incorpora-
tion of ara-CTP into the DNA blocks DNA synthesis and leads to cell
death. Ara-CTP formation can be obstructed. Pyrimidine nucleotidase I
(PN-I; 3) opposes the action of dCK. Cytidine deaminase (CDA; 4) and
deoxycytidylate deaminase (dCMPD; 5) convert ara-C to ara-U, and ara-
CMP to ara-UMP, respectively. Increased intracellular dCTP pools
antagonise the formation of ara-CTP. dCTP can be synthesised directly
via the de novo pathway by ribonucleotide reductase (6). CTP synthetase
(CTPs; 7) converts uridine triphosphate to CTP. Because aberrant
expression of these enzymes may be related to in vitro sensitivity to ara-
C, and other deoxynucleoside analogues, we determined the mRNA
expression of the target genes in AML.
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Mononuclear cells were isolated by density gradient centrifugation
using Lymphoprep (density 1.077gml
 1; Nycomed Pharma, Oslo,
Norway), and centrifuged at 480g for 15min at room temperature.
Cells were washed and resuspended in culture medium consisting
of RPMI 1640 medium (Dutch modification without L-glutamine;
Gibco BRL, Life Technologies, Breda, The Netherlands), 20%
fetal calf serum (FCS; Integro, Zaandam, The Netherlands), 2mM
L-glutamine (Gibco BRL, Life Technologies), 5mgml
 1 transferrin,
5ngml
 1 sodium selenite (ITS media supplement; Sigma, St Louis,
MO, USA), 100IUml
 1 penicillin, 100mgml
 1 streptomycin,
0.125mgml
 1 fungizone (Gibco BRL, Life technologies), and
0.2mgml
 1 gentamycin (Gibco BRL, Life technologies). Contam-
inating normal cells were removed by immunomagnetic beads (in
case of lymphocytes) or by freezing in liquid nitrogen and thawing
(in case of granulocytes) (Kaspers et al, 1994b). All samples
contained at least 80% leukemic cells, as determined morpholo-
gically on May–Grunwald–Giemsa (Merck, Darmstadt, Germany)
stained cytospins. A minimum of 5 10
6 cells were lysed in
RNAzol or Trizol reagent (Gibco BRL, Life technologies) and
stored at  801C until RNA extraction. The majority of samples
were received and processed within 24h (n¼42), eight samples
however were received and processed within 48h.
RNA extraction and cDNA synthesis
Total cellular RNA was isolated from 5 10
6 cells using RNAzol or
Trizol reagent, according to the manufacturer’s protocol. After
precipitation with ethanol, RNA pellets were dissolved in water.
The RNA was quantitated spectrophotometrically. cDNA synthesis
was performed as described by Stam et al (2003). Briefly, following
a denaturation step of 5min at 701C, 1mg of RNA was reverse
transcribed to single-stranded cDNA using a mix of random
hexamers (2.5mM) and oligo dT primers (20nM). The RT reaction
was performed in a total volume of 25ml containing 0.2mM of each
dNTP (Amersham Pharmacia, Biotech, Piscataway, NJ, USA) 200U
Moloney murine leukaemia virus reverse transcriptase (M-ML RT;
Promega, Madison, WI, USA), and 25U RNAsin (Promega) at 371C
for 30min, 421C for 15min and 941C for 5min. The obtained
cDNA was diluted to a final concentration of 8ngml
 1. Samples
were stored at  801C.
Quantitative real-time PCR (Taqman technology)
The mRNA expression levels of dCK, PN-I, CDA, dCMPD, hENT1,
RR1 and RR2, CTP synthetase and the endogenous housekeeping
gene encoding glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) as a reference were quantified using real-time PCR
analysis (Taqman) on an ABI Prism 7700 sequence detection
system (PE Applied Biosystems). Amplification of specific PCR
products was detected using dual-fluorescent nonextendable
probes labelled with 6-carboxyfluorescein (FAM) at the 50 end
and with 6-carboxytetramethylrhodamine (TAMRA) at the 30 end.
All primers and probe combinations were designed using the
OLIGO 6.22 software (Molecular Biology Insights, Cascade, CO,
USA) and purchased from Eurogentec (Seraing, Belgium). Primers
and probes used to detect hENT1, dCK, PN-I, CDA and dCMPD
have been reported before (Stam et al, 2003). For CTPs and RR1
and RR2 primers and probes are listed in Table 1.
As described before (Stam et al, 2003), real-time PCR was
performed in a total reaction volume of 50ml containing TaqMan
buffer A (Applied Biosystems, Nieuwerkerk a/d Ijssel, The
Netherlands), 4mM MgCl2, 200mM of each dNTP (Amersham
Pharmacia Biotech), 300nM forward and reverse primer, 50nM
dual-labelled fluorogenic internal probe, 1.25U AmpliTaq Gold
DNA polymerase (Applied Biosystems) and 40ng of cDNA as a
template. Samples were heated for 10min at 951C to activate the
AmpliTaq Gold DNA polymerase and amplified during 40 cycles of
15s at 951C and 60s at 601C. The relative mRNA expression levels
of the target genes in each patient were calculated using the
comparative cycle time (Ct) method (Meijerink et al, 2001). Briefly,
this PCR Ct value is the cycle number at which emitted
fluorescence exceeds 10 the standard deviation (s.d.) of baseline
emissions as measured from cycles 3–15. The Ct of the target gene
is normalised to the GAPDH PCR Ct value by subtracting the
GAPDH Ct value from the target Ct value. The mRNA expression
level for each target PCR relative to GAPDH can was calculated
using the following equation:
relativemRNAexpression ¼ 2 ðCt target Ct GAPDHÞ 100%
In vitro cytotoxicity assay
In vitro cytotoxicity of the deoxynucleoside analogues ara-C
(Cytosar; Pharmacia &Upjohn, Woerden, The Netherlands), 2-CdA
(Leustatin, Ortho Biotech, USA), DAC (Decitabine, kindly
provided by PCH Pharmachemie bv, Haarlem, The Netherlands),
F-ara-A (Fludara, Schering AG, The Netherlands), Gemcitabine
(Gemzar, Eli Lilly, Houten, The Netherlands) was determined
using the MTT-assay as described previously (Pieters et al, 1990).
Briefly, cells were cultured in round-bottomed 96-well microtitre
plates in the presence of six concentrations of different drugs,
in the following ranges: ara-C (0.04–41.0mM); 2-CdA (0.001–
140.0mM); DAC (11.0mM–11.0mM); F-ara-A (0.04–44.0mM) and
dFdC (0.04–13.0mM). Cells without drugs were included as
controls and cells in culture medium only were used as blanks.
The plates were cultured for 4 days at 371C in humidified air
containing 5% CO2, after which 10ml of 3-[4,5-dimethylthiazol-2-
yl]-2,5 diphenyl tetrazoliumbromide (MTT; 5mgml
 1, Sigma
Aldrich, Zwijndrecht, The Netherlands) was added and the plates
were incubated for an additional 6h. Only viable cells are able to
reduce MTT tetrazolium salt to purple/blue formazan crystals. The
formazan crystals were dissolved using acidified isopropanol
(0.04 N HCl-isopropyl alcohol) and the optical density (OD), which
is linearly related to the number of viable cells, (Klumper et al,
1995) was measured spectophotometrically at 562 and 720nM.
After subtraction of the blank values, the leukemic cell survival
(LCS) was calculated by the following equation: LCS¼(ODday4
treated well/mean ODday4 control wells) 100%. Drug sensitivity
was expressed as the LC50 value, the drug concentration lethal to
50% of the leukemic cells. Evaluable results were obtained when a
Table 1 Primers and probe combinations used for the quantitative real-
time PCR
Gene Sequence
RR1
Forward 50-GTG TGG GAA ATC TCT CAG A-30
Reverse 50-CCA TGG CTG CTG TGT T-30
Probe 50-(FAM)-CAA ACT CAC TAG TAT GCA CTT CTA
CGG-(TAMRA)-30
RR2
Forward 50-AGG GGC TCA GCT TGG-30
Reverse 50-GGG GCA GCT GCT TTA G-30
Probe 50-(FAM)-CGT CCT GGC CAG CAA GAC-(TAMRA)-30
CTPs
Forward 50-ATC CCG TGG TCG TAG AC-30
Reverse 50-TGG CCA ACA AAC TTC AA-30
Probe 50-(FAM)-AAC ACA ACC CAG GGC AGA TG-(TAMRA)-30
RR1¼ribonucleotide reductase subunit 1; RR2¼ribonucleotide reductase subunit 2;
CTPs¼CTP synthetase.
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control OD was more than or equal to 0.050 (Kaspers et al, 1994a).
Sample source (bone marrow or peripheral blood) and cryo-
preservation do not influence the results obtained by cellular drug
resistance testing and were therefore analysed together (Kaspers
et al, 1991).
Statistics
Distribution of measurement values was characterised with
median and quartiles (25th–75th percentiles). Due to the strongly
skewed character of the distributions, analyses were performed on
the log-transformed measurements. For significance, a two-tailed
level of a¼0.01 was used. P-values between 0.01 and 0.05 were
considered to indicate a trend for significance. Pearson correla-
tions were used to describe relations between variables. AML
patient samples were divided in thre subgroups, according to their
sensitivity to ara-C: sensitive (LC50o0.98mM), intermediate
(0.98oLC50o5.18mM) and resistant (LC5045.18mM) (cutoffs
based on Zwaan ChM, Blood, 2000) (Zwaan et al, 2000) and a
one-way ANOVA was carried out on hENT1 for these three
sensitivity groups. Stepwise modelling on the log-transformed LC50
values was used to unravel the relative importance of the possible
indicators.
RESULTS
Patient characteristics
Fifty-five AML patient samples with LC50 values for ara-C,
cladribine, decitabine, fludarabine and gemcitabine (determined
with the MTT assay) were selected for RNA isolation. We were
unable to isolate a sufficient amount of RNA from five of these
samples. Thus, the study population consists of 50 newly
diagnosed paediatric AML patients. Patient characteristics are
listed in Table 2. This selected group of AML patients did not differ
significantly with regard to age (P¼0.30), WBC (P¼0.14), sex
(P¼0.39) or in vitro sensitivity to ara-C (P¼0.50) from a large
group of AML samples that we have previously characterised for in
vitro drug sensitivity (Hubeek et al, submitted; Zwaan et al, 2000)
and was therefore considered to be representative.
mRNA expression levels of enzymes involved in the
metabolism of deoxynucleoside analogues in AML and
FAB-type subgroups
Using quantitative real-time PCR the mRNA expression levels of
hENT1, dCK, PN-I, CDA, dCMPd, RR1, RR2 and CTPs were
determined. Measurable amounts of all eight genes were found in
all samples. Sample source (bone marrow (n¼37) or peripheral
blood (n¼13)) and the time interval between tissue acquisition
and processing/storage of the cells (within 24 or 48h) did not
influence mRNA expression of the enzymes and all samples were
therefore evaluated together in the following analyses. Genes were
expressed with considerable variability between various patients
(Figure 2). We investigated the association between all eight genes
and several diagnostic features. There was no difference in mRNA
expression levels of target genes between boys and girls, nor was
there a relation between the expression level of these genes and
initial white blood cell (WBC) count.
For the analysis with FAB-type, patients were divided into three
subgroups: FAB M1/M2, FAB M4 and FAB M5. FAB M1/M2 were
taken together because they did not differ in age, sex, WBC, drug
resistance or mRNA expression levels (data not shown). FAB M0
and FAB M3 were excluded because of the limited number of
samples. FAB M5 expressed 1.8-fold (P¼0.007) lower levels of
PN-I compared to FAB M1/M2. We did not observe any other
significant differences (Table 3).
Table 2 Patient characteristics
Patient characteristics n
Sex (male:female) 31:19
Age, years (median, range) 10.7 (0.1–16.8)
WBC (median, range) 79.3 10
9l
 1 (2.1–524.0)
FAB-type
M0 2
M1 6
M2 8
M3 4
M4 18
M5 9
Unknown 3
WBC¼white blood cell count.
hENT1 dCK CDA dCMPD PN-I RR1 RR2 CTPs
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Figure 2 Expression levels of potential resistance factors to ara-C,
determined by Taqman PCR. mRNA expression (relative to glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH)) of the human equilibrative
nucleoside transporter 1 (hENT1), deoxycytidine kinase (dCK), pyrimidine
nucleotidase I (PN-I), cytidine deaminase (CDA), ribonucleotide reductase
subunit 1 and 2 (RR1 & RR2) and CTP synthetase (CTPs) were determined
by Taqman PCR in 50 paediatric AML samples, obtained at diagnosis.
Measurable amounts of all genes were found in all patients. Targets were
expressed with great variability; group medians, 25th/75th percentiles and
the ranges are given.
Table 3 mRNA expression (relative to GAPDH (%)) of hENT1 and
enzymes involved in ara-C cytotoxicity in AML FAB type subgroups
FAB M1/2 FAB M4 FAB M5
(n¼14) (n¼18) (n¼9)
hENT1 0.68 (0.30–0.76) 0.51 (0.33–0.75) 0.57 (0.48–0.95)
DCK 0.61 (0.45–1.34) 0.52 (0.42–0.89) 0.55 (0.17–0.85)
CDA 0.069 (0.009–0.24) 0.14 (0.06–0.20) 0.16 (0.08–0.21)
DCMPd 1.09 (0.72–1.56) 0.89 (0.70–1.19) 0.60 (0.52–1.09)
PN-I 0.79 (0.51–1.37) 0.60 (0.39–0.85) 0.43 (0.16–0.50)*
RR1 0.18 (0.11–0.29) 0.15 (0.06–0.22) 0.15 (0.08–0.22)
RR2 0.05 (0.02–0.09) 0.04 (0.01–0.08) 0.05 (0.02–0.17)
CTPs 0.28 (0.20–0.32) 0.20 (0.14–0.33) 0.34 (0.17–0.47)
Values are the group median (25th–75th percentile). *Po0.01 compared to FAB
M1/2.
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Dose–response curves were obtained for all drugs and marked
differences between individual patients were found. The median
(25th–75th percentile) ara-C LC50 value was 1.70mM (0.59–
3.38mM; n¼50), which is in concordance with results published
previously (Zwaan et al, 2000). For the purine analogues 2-CdA
and F-ara-A group median LC50 values were 0.073mM (0.051–
0.098mM; n¼46) and 1.19mM (0.66–2.27mM; n¼47), respectively.
The group median for dFdC was 10.04mM (2.05–20.86mM; n¼48),
while DAC was only active in very high concentrations (median
LC50 value¼3426mM (717–5700mM; n¼48)).
Correlations between mRNA expression levels and in vitro
sensitivity to deoxynucleoside analogues
hENT1 mRNA expression inversely correlated with the LC50 values
of ara-C (rp¼ 0.46; P¼0.001; n¼50) and also seemed to
correlate inversely with the LC50 values of 2-CdA (rp¼ 0.30;
P¼0.04; n¼46), DAC (rp¼ 0.29; P¼0.04; n¼48) and dFdC
(rp¼ 0.33; P¼0.02; n¼48). In other words, increased sensitivity
to deoxynucleoside analogues was directly related to increased
mRNA expression of the hENT1 nucleoside transporter. Further-
more, decreased dCK mRNA expression seemed to correlate with
resistance to dFdC (rp¼ 0.31; P¼0.03; n¼48). Also, resistance
to DAC seemed to correlate with increased CDA mRNA levels
(rp¼0.33; P¼0.03; n¼48). The accumulation of ara-CTP could
depend on the ratio of the activation enzyme dCK and the
inactivation enzymes PN-I and CDA. Therefore, we also studied the
relation between the dCK/PN-I and dCK/CDA ratios and in vitro
drug sensitivity. The dCK/PN-I ratio correlated inversely with the
LC50 values for dFdC (rp¼ 0.45; P¼0.001; n¼47) and the dCK/
CDA ratio seemed to correlate with the LC50 values for DAC
(rp¼ 0.29; 0.04; n¼48). We did not observe correlations between
these ratios and in vitro sensitivity to ara-C, 2-CdA and F-ara
(Table 4).
mRNA expression levels of hENT1, dCK, PN-I, CDA, dCMPd,
RR1/2 and CTPs were entered into a stepwise multivariate
regression model to identify the most important indicators with
respect to in vitro sensitivity to deoxynucleoside analogues
(dependent variables LC50 values ara-C, 2-CdA, DAC, F-ara-A or
dFdC). In multivariate analysis, hENT1 mRNA expression
predicted in vitro sensitivity to ara-C (P¼0.002). Furthermore,
CDA mRNA expression levels seemed to predict in vitro sensitivity
to DAC (P¼0.02), while other factors did not reach significance.
Also, when we divided the AML samples in three subgroups based
on their in vitro ara-C sensitivity, resistant patients expressed
three-fold lower hENT1 mRNA levels compared to sensitive
patients (P¼0.003; Figure 3).
DISCUSSSION
For AML, ara-C is the essential drug during induction and
consolidation therapy and is given both at intermediate and high-
dose schedules (Bloomfield et al, 1998; Galmarini et al, 2002a). In
the present study we analysed possible resistance factors to ara-C,
and other clinically important deoxynucleoside analogues, in AML
by measuring the gene expression of the major players in transport
and metabolism of ara-C. Quantitative real-time PCR revealed
that AML FAB-M5 expressed lower levels of the ara-C degrading
enzyme PN-I compared to FAB-M1/2. Although the analysis
included only a limited number of samples, this finding may
provide an explanation for the relative sensitivity to ara-C of AML
FAB-M5 that we reported previously (Zwaan et al, 2000).
We studied the relation between the mRNA expression level of
potential ara-C resistance factors and in vitro sensitivity to
deoxynucleoside analogues. Although in vitro drug resistance
testing differs considerably from the in vivo situation, it does
provide valuable indications as to which factors might be
important in drug sensitivity in vivo (Kaspers et al, 1999). hENT1
mRNA expression correlated with sensitivity to ara-C and also
seemed to correlate with sensitivity to 2-CdA, DAC and dFdC,
indicating that transport across the cell membrane is an important
step for deoxynucleoside analogue induced cytotoxicity. In multi-
variate analysis, hENT1 mRNA expression was the most important
factor determining sensitivity to ara-C. This might be explained by
the fact that entry of ara-C into the cell is mainly dependent on
hENT1-mediated transport (Wiley et al, 1982; Pastor-Anglada
et al, 1998; Sundaram et al, 2001; Clarke et al, 2002). In contrast,
2-CdA, DAC and dFdC differ from ara-C with respect to their
preferential nucleoside transporters and can be transported across
the cell membrane by other members of the nucleoside transporter
family as well (Damaraju et al, 2003). 2-CdA can enter cells via
hENT1, hENT2 and the human concentrative nucleoside trans-
porter (hCNT) 3 (Ritzel et al, 2001; Damaraju et al, 2003), while
hENT1, hENT2, hCNT1 and hCNT3 are able to mediate uptake of
dFdC into cells (Damaraju et al, 2003). hENT1 mediated influx
however seems to be a pivotal factor in ara-C cytotoxicity. Patients
Sensitive (n=16) Intermediate (n=23) Resistant (n=11)
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Figure 3 hENT1 mRNA expression in relation to in vitro ara-C sensitivity.
AML patient samples were divided into three groups based on in vitro
ara-C sensitivity (sensitive¼LC50o0.98mM), intermediate¼0.98oLC50
o5.18mM) and resistant¼LC5045.18mM) (Zwaan et al, 2000). Patient
resistant to ara-C in vitro expressed 3.0-fold lower hENT1 mRNA levels
compared to sensitive patients. The lines indicate the median value. P-value
determined by one-way ANOVA.
Table 4 Correlation between mRNA level of potential resistance factors
and in vitro sensitivity to deoxynucleoside analogues (expressed as LC50
values) in 50 paediatric AML samples obtained at initial diagnosis
Ara-C 2-CdA DAC F-ara-A dFdC
hENT1 rp  0.46**  0.30*  0.29*  0.24  0.38*
P-value 0.001 0.04 0.04 0.09 0.02
dCK rp  0.11  0.09  0.04 0.004  0.31*
P-value 0.43 0.55 0.79 0.98 0.03
CDA rp 0.13  0.09 0.33* 0.06 0.001
P-value 0.38 0.57 0.02 0.69 0.99
dCK/PN-1 rp  0.27  0.09  0.16  0.26  0.45**
P-value 0.06 0.55 0.29 0.08 0.001
dCK/CDA rp  0.17 0.02 0.29*  0.05  0.18
P-value 0.24 0.87 0.04 0.75 0.23
**Pearson correlation (rp) significant at the 0.01 level (two-tailed). *Pearson
correlation (rp) significant at the 0.05 level (two-tailed). Correlations between mRNA
expression of dCMPD, PN-I, RR1, RR2 and CTPs, and in vitro sensitivity to
deoxynucleoside analogues were not significant.
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levels. Our results are supported by the fact that hENT1 has been
implicated as a crucial factor in ara-C sensitivity in previous
studies (Galmarini et al, 2002b,c). Galmarini et al measured
hENT1 mRNA expression in adult AML samples and demonstrated
that hENT1 deficiency was related to a shorter disease-free survival
(Galmarini et al, 2002c). In addition, elevated hENT1 mRNA
expression explained the remarkable ara-C sensitivity of infants
with MLL gene-rearranged ALL (Stam et al, 2003). hENT1 may
therefore be a valuable predictor of ara-C sensitivity at diagnosis.
Unfortunately, we were not able to asses the relation between
hENT1 expression and in vivo response to treatment due to the
heterogenity of the treatment and the limited follow-up time.
Patients were treated according to different treatment protocols
and several different dosing schedules. AML patients may however
benefit from screening for hENT1 mRNA levels at diagnosis,
because of its significance for ara-C dosing. At intermediate dose
ara-C (100–200mgm
 2) plasma levels are in the mM range and
transport across the cell membrane is solely dependent on
nucleoside transporters (Peters et al, 1993). At high-dose ara-C
(1–3gm
 2), however, hENT1 seems less crucial although plasma
concentrations might not exceed the Km of the transporter
mediated influx. Ara-C may also enter by passive diffusion at this
concentration, while dCK will be saturated (Capizzi et al, 1985;
Bolwell et al, 1988). Patients with a low hENT1 mRNA level could
potentially benefit from up-front high dose ara-C treatment or an
ara-C analogue that is not dependent on transporter-mediated
influx. A compound such as troxacitabine, which passively diffuses
across the cell membrane due to its unusual L-configuration
(Gourdeau et al, 2001; Giles, 2002), might be able to circumvent
ara-C resistance caused by low hENT1 expression.
Most studies on ara-C resistance have focussed on the
conversion of ara-C to ara-CTP and several studies have linked
reduced dCK mRNA expression or functional activity to ara-C
resistance (Owens et al, 1992; Stegmann et al, 1993; Kawasaki et al,
1996; Dumontet et al, 1999). In acute leukaemia, relapsed ALL and
AML patients have been shown to express decreased dCK mRNA
levels (Kakihara et al, 1998). In contrast, dCK was not rate-limiting
in the formation of ara-CTP in infants with MLL gene-rearranged
ALL (Stam et al, 2003). In this present study, we did not observe a
correlation between dCK mRNA expression and in vitro ara-C
sensitivity in AML blasts. Although there was a considerable range
in dCK mRNA levels in AML blasts, the median expression was
quite high, and it therefore seems unlikely that low dCK expression
plays a role in ara-C resistance in childhood AML at diagnosis. We
have previously reported on dCK mRNA levels in childhood AML
blasts and most AML samples expressed mRNA leves that were in
the range of cell lines sensitive to ara-C (van der Wilt et al, 2003).
Reduced dCK mRNA expression may however be involved in
resistance to gemcitabine. Both dCK mRNA and protein levels have
been shown to predict in vivo gemcitabine sensitivity (Kroep et al,
2002). Our present study also indicated that reduced dCK mRNA
expression may contribute to in vitro gemcitabine resistance in
AML blasts. It should be mentioned, however, that the Pearson
correlation coefficient was low and was not significant in
multivariate analysis.
Finally, multivariate analysis showed that DAC resistance
seemed to correlate with increased mRNA levels of the inactivating
enzyme CDA. DAC was initially developed as a cytotoxic agent and
has activity in several haematological malignancies. Low-dose DAC
is currently enjoying a revival as a specific inhibitor of DNA
hypermethylation in cancer (Lyons et al, 2003). DAC is an
excellent substrate for CDA and elevated CDA mRNA levels might
contribute to resistance to DAC (Momparler, 1985).
In conclusion, our findings indicate that reduced drug influx
into the cell caused by decreased hENT1 mRNA expression might
be involved in resistance to ara-C, and other deoxynucleoside
analogues, in childhood AML.
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